LY-2183240 is a drug which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. This leads to markedly elevated anandamide levels in the brain, and LY-2183240 has been shown to produce both analgesic and anxiolytic effects in animal models. While LY-2183240 is a potent inhibitor of FAAH, it has relatively poor selectivity and also inhibits several other enzyme side targets. Consequently, it was never developed for clinical use, though it remains widely used in research, and has also been sold as a designer drug. See also Endocannabinoid reuptake inhibitor FAAH inhibitor BIA 10-2474 PF-04457845 URB-597 References Further reading Cannabinoids Endocannabinoid reuptake inhibitors Eli Lilly and Company brands Designer drugs Tetrazoles